Sun Pharma ’s Phase III trials of Baclofen GRS fail to meet primary endpoint

India-based Sun Pharma Advanced Research (SPARC) has reported top-line results from two Phase III clinical trials of Baclofen GRS to treat spasticity in patients suffering from multiple sclerosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Evaluating the usefulness of treatment requires a direct measurement of the health-related quality of life (QOL). Therefore, this study was carried out aiming to determine the QOL of patients with MS and voidi...
Source: BMC Urology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
Source: Journal of Neurology - Category: Neurology Source Type: research
A critical role for IL-17, a cytokine produced by T helper 17 (Th17) cells, has been indicated in the pathogenesis of chronic inflammatory and autoimmune diseases. A positive effect of blockade of IL-17 secreted by autoreactive T cells has been shown in various inflammatory diseases. Several cytokines, whose production is affected by environmental factors, control Th17 differentiation and its maintenance in tissues during chronic inflammation. The roles of IL-17 in the pathogenesis of chronic neuroinflammatory conditions, multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE), Alzheimer's disease, and isc...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Mazzon Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system. It represents one of the main causes of neurological disability in young people. In MS, the autoimmune response is directed against myelin antigens but other possible bio-molecular markers are investigated. The aim of this work was, through an in silico study, the evaluation of the transcriptional modifications between healthy subjects and MS patients in six brain areas (corpus callosum, hippocampus, internal capsule, optic chiasm, frontal and parietal cortex) in order to identify genes representative of the dis...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
AbstractMultiple sclerosis (MS) is a neuroinflammatory disease in which unresolved and uncontrolled inflammation disrupts normal cellular homeostasis and leads to a pathological disease state. It has long been recognized that endogenously derived metabolic by-products of omega fatty acids, known as specialized pro-resolving lipid mediators (SPMs), are instrumental in resolving the pathologic inflammation. However, there is minimal data available on the functional status of SPMs in MS, despite the fact that MS presents a classical model of chronic inflammation. Studies to date indicate that dysfunction of the SPM biosynthet...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
The U.S. Food and Drug Administration has extended the review period for Novartis AG's multiple sclerosis drug ofatumumab by three months, the company said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
This study aims to identify reliable and objective gait-based biomarkers to monitor progressive multiple sclerosis (MS) in clinical s...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Authors: Smolders J, Fransen NL, Hsiao CC, Hamann J, Huitinga I Abstract INTRODUCTION: Multiple sclerosis (MS) is characterized by inflammatory attacks of infiltrating leukocytes at onset but evolves into a smoldering, progressive disease within the central nervous system at its later stages. The authors discuss the contribution of white matter lesions to the pathology of advanced MS, thereby paying particular attention to the role of T cells. AREAS COVERED: Diagnostic biopsy and autopsy studies of white matter lesions in early MS show different pathological patterns of demyelination and leukocyte infiltration. Bra...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
Publication date: Available online 2 June 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Virginia Meca-Lallana, Clara Aguirre, Laura Cardeñoso, Teresa Alarcon, Angels Figuerola-Tejerina, Beatriz del Río, Miguel Ruiz Álvarez, José Vivancos
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Condition:   Secondary Progressive Multiple Sclerosis Interventions:   Drug: SAR442168;   Drug: Placebo to match SAR442168 Sponsor:   Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Baclofen | Clinical Trials | India Health | Multiple Sclerosis | Pharmaceuticals